Affimed GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Affimed GmbH (Affimed), formerly Affimed Therapeutics AG, a subsidiary of Affimed NV, is a clinical stage biopharmaceutical company which discovers and develops targeted cancer immunotherapies. The companys pipeline product candidates include AFM11, AFM12, AFM13, AFM21 and AFM22, among others. Its AFM13 is in Phase I trials for the treatment of Hodgkins lymphoma; and AFM11 is in late formal pre-clinical development for the treatment of non-Hodgkins lymphoma. Affimeds discovery portfolio also includes AFM15, HSAxCD3 in preclinical trials, and others. The company has operations with offices in Czech Republic and the US. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany.

Affimed GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Affimed GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Affimed GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Affimed GmbH, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Amphivena Therapeutics Raises US$14 Million In Series A Financing 11
Affimed Therapeutics Raises US$20.2 Million In Series D Financing 12
Equity Offering 14
Affimed Raises USD21.8 Million in Private Placement of Shares 14
Affimed Therapeutics Raises USD56 Million in IPO 15
Acquisition 17
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 17
Affimed GmbH - Key Competitors 18
Affimed GmbH - Key Employees 19
Affimed GmbH - Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Aug 08, 2018: Affimed reports financial results for second quarter 2018 and operational progress 21
May 15, 2018: Affimed Reports Financial Results for First Quarter 2018 24
Mar 20, 2018: Affimed Reports Financial Results for Fourth Quarter and Year End 2017 26
Corporate Communications 28
Mar 19, 2018: Affimed Appoints Dr. Leila Alland as Chief Medical Officer 28
Product News 29
May 03, 2018: Affimed Introduces ROCK Platform for Tailored Immune Cell Engagers 29
03/01/2017: Affimed to Present Data on AFM13 at the AACR Annual Meeting 2017 30
03/01/2017: Affimed to Present Data on lead candidate AFM24 at the AACR Annual Meeting 2017 31
03/01/2017: Affimed to Present Data on lead candidate AFM26 at the AACR Annual Meeting 2017 32
03/01/2017: Affimed to Present Data on Monoclonal Antibodies to Target HLA-A2 and CD3 for Oncology at the AACR Annual Meeting 2017 33
Clinical Trials 34
Jun 15, 2018: Affimed Announces Updated Data of AFM13 in Combination with Keytruda (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA 34
Mar 15, 2018: Affimed to Present Data on AFM24 at AACR Annual Meeting 2018 35
Feb 01, 2018: Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas 36
Dec 11, 2017: Affimed Presents Data From Phase 1b Combination Study of AFM13 With Pembrolizumab at ASH 38
Dec 11, 2017: Affimed Presents Preclinical Data on AFM26 at American Society of Hematology (Ash) Annual Meeting and Exposition 2017 40
Jun 27, 2017: Affimed Presents Preclinical Data on AFM24 at EACR-AACR-SIC 2017 41
Jun 27, 2017: Affimed Presents Preclinical Data on AFM26 at EACR-AACR-SIC 2017 42
Jun 06, 2017: Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017 43
May 17, 2017: Affimed to Present Data for Preclinical AFM24 Program at ASCO Annual Meeting and EACR-AACR-SIC Special Conference 44
May 17, 2017: Affimed to Present Data for Preclinical AFM26 Program at ASCO Annual Meeting and EACR-AACR-SIC Special Conference 45
Apr 05, 2017: Affimed Presents Data on MHC-peptide-targeting discovery program at the AACR Annual Meeting 2017 46
Apr 05, 2017: Affimed Presents Data on Preclinical Program AFM-26 at the AACR Annual Meeting 2017 47
Apr 05, 2017: Affimed Presents Data on Preclinical Program AFM24 at the AACR Annual Meeting 2017 48
Apr 05, 2017: Affimed Presents Preclinical Data on AFM13 at the AACR Annual Meeting 2017 49
Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM13 50
Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM24 52
Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM26 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List Of Tables


Affimed GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Affimed GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Affimed GmbH, Deals By Therapy Area, 2012 to YTD 2018 9
Affimed GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amphivena Therapeutics Raises US$14 Million In Series A Financing 11
Affimed Therapeutics Raises US$20.2 Million In Series D Financing 12
Affimed Raises USD21.8 Million in Private Placement of Shares 14
Affimed Therapeutics Raises USD56 Million in IPO 15
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 17
Affimed GmbH, Key Competitors 18
Affimed GmbH, Key Employees 19

List Of Figures


Affimed GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Affimed GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Affimed GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Affimed GmbH (Affimed), formerly Affimed Therapeutics AG, a subsidiary of Affimed NV, is a clinical stage biopharmaceutical company which discovers and develops targeted cancer immunotherapies. The companys pipeline product candidates

USD 250 View Report

Affimed GmbH - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Affimed GmbH (Affimed), formerly Affimed Therapeutics AG, a subsidiary of Affimed NV, is a clinical stage biopharmaceutical company which discovers and develops targeted cancer immunotherapies. The companys pipeline product candidates

USD 250 View Report

Gilupi GmbH - Product Pipeline Analysis, 2019 Update

Gilupi GmbH (Gilupi) is a medical device company that develops and manufactures devices for the in vivo isolation of rare cells from the circulation. The company develops medical detector that

USD 750 View Report

Oettinger Brauerei GmbH - Strategy, SWOT and Corporate Finance Report

Oettinger Brauerei GmbH - Strategy, SWOT and Corporate Finance ReportOettinger Brauerei GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available